IVERIC bio (NASDAQ: ISEE)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-08 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.310 | -0.410 | -0.1000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of IVERIC bio (NASDAQ: ISEE) through any online brokerage.
Other companies in IVERIC bio’s space includes: Zentalis Pharmaceuticals (NASDAQ:ZNTL), Chinook Therapeutics (NASDAQ:KDNY), Syndax Pharmaceuticals (NASDAQ:SNDX), Prothena Corp (NASDAQ:PRTA) and Arcutis Biotherapeutics (NASDAQ:ARQT).
The latest price target for IVERIC bio (NASDAQ: ISEE) was reported by UBS on Tuesday, August 2, 2022. The analyst firm set a price target for 20.00 expecting ISEE to rise to within 12 months (a possible 55.64% upside). 12 analyst firms have reported ratings in the last year.
The stock price for IVERIC bio (NASDAQ: ISEE) is $12.85 last updated Today at August 17, 2022, 5:24 PM UTC.
There are no upcoming dividends for IVERIC bio.
IVERIC bio’s Q3 earnings are confirmed for Tuesday, November 8, 2022.
There is no upcoming split for IVERIC bio.
IVERIC bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.